Print

Vanderbilt University and Bristol-Myers Squibb Company (BMY) Sign Collaboration Agreement to Develop Novel Treatments for Parkinson’s Disease  
9/21/2012 10:09:15 AM

NASHVILLE, Tenn. & NEW YORK--(BUSINESS WIRE)--Vanderbilt University and Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson’s disease.